← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Itron contracted revenue, remained profitable, generated positive free cash flow at a 13.2% operating margin. Stock compensation grew faster than revenue, while profit and free cash flow remained strong.
The read at a glance✓ Audited against SEC data
- Growth — Revenue declined 3.0%Watch
- Profitability — Net income grew 25.9% to $301.055M from $239.105MOK
- Cash flow — Free cash flow grew 84.5% to $383.061M from $207.613MOK
- Margins — Operating margin expanded 241 bps to 13.23%OK
- Accounting — Stock compensation grew faster than revenue, while profit and free cash flow remained strongNote
- Insiders — 0 purchases and 65 salesWatch
Business
Itron provides smart meters, grid software and connected infrastructure.
Where the revenue comes from
Fiscal 2025, as ITRON, INC. reports it. History and quarterly detail are in the app.
- Networked Solutions$1.6B
- Device Solutions$447.1M
- Outcomes$359.7M
- Resiliency Solutions$3.0M
Leadership changes
From ITRON, INC.'s own filings, the day they're filed.
- Scott Drury · director · departureeff. 2025-08-20
- Sheri Savage · director · appointmenteff. 2025-08-11
- Sanjay Mirchandani · director · appointmenteff. 2023-07-18
Latest filings
- 8-K · Company announcement2026-07-28
- 10-Q · Quarterly report2026-07-28
- 8-K · Company announcement2026-05-08
- 8-K · Company announcement2026-04-28
- 10-Q · Quarterly report2026-04-28
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about ITRON, INC., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.